

PRK2 (4C2) Mouse mAb

Catalog # AP53508

Product Information

Application WB, IHC-P, FC **Primary Accession** O16513

Reactivity Rat, Human, Mouse, Monkey

Host Mouse

Clonality Monoclonal Antibody

Isotype IgG1

Conjugate Unconjugated

Immunogen Purified recombinant fragment of human PRK2 expressed in E. Coli.

Purification Ascitic Fluid Calculated MW 112035

Additional Information

Gene ID 5586

Other Names PKN2; PAK2; PRK2; Pak-2; PRKCL2; PRO2042; MGC71074; MGC150606

Dilution WB~~1:500 IHC-P~~N/A FC~~1:10~50

Format Liquid in Purified antibody in PBS with 0.05% sodium azide.

Storage Store at 4°C short term. Aliquot and store at -20°C long term. Avoid

freeze/thaw cycles.

Protein Information

Name PKN2

Synonyms PRK2, PRKCL2

Function PKC-related serine/threonine-protein kinase and Rho/Rac effector protein

that participates in specific signal transduction responses in the cell. Plays a role in the regulation of cell cycle progression, actin cytoskeleton assembly, cell migration, cell adhesion, tumor cell invasion and transcription activation signaling processes. Phosphorylates CTTN in hyaluronan-induced astrocytes and hence decreases CTTN ability to associate with filamentous actin.

Phosphorylates HDAC5, therefore lead to impair HDAC5 import. Direct RhoA target required for the regulation of the maturation of primordial junctions into apical junction formation in bronchial epithelial cells. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Stimulates FYN kinase activity that is required for establishment of skin cell-cell adhesion during keratinocytes differentiation. Regulates epithelial bladder cells speed and direction of movement during

cell migration and tumor cell invasion. Inhibits Akt pro-survival-induced kinase activity. Mediates Rho protein-induced transcriptional activation via the c-fos serum response factor (SRF). Involved in the negative regulation of ciliogenesis (PubMed:27104747).

Cellular Location

Cytoplasm. Nucleus Membrane {ECO:0000250 | UniProtKB:Q8BWW9}. Cell projection, lamellipodium. Cytoplasm, cytoskeleton. Cleavage furrow. Midbody Cell junction. Note=Colocalizes with PTPN13 in lamellipodia-like structures, regions of large actin turnover. Accumulates during telophase at the cleavage furrow and concentrates finally around the midbody in cytokinesis. Recruited to nascent cell-cell contacts at the apical surface of cells. In the course of viral infection, colocalizes with HCV NS5B at perinuclear region in the cytoplasm.


Tissue Location

Ubiquitous. Expressed in numerous tumor cell lines, especially in bladder tumor cells.


Background

Swiss-Prot Acc.Q16513.Protein-kinase-C-related kinases (PRKs) are part of the lipid-regulated protein kinases (PKC) which also include liver PAK & PKN. Human PRK1 and PRK2 share structurally similar catalytic domains, but less similar N-terminal regulatory regions suggesting different regulatory domain functions. PRK1 and PRK2, as well as a third member of this family, PRK3, show distinct patterns of expression in adult tissues. Additionally, the serine-threonine kinase PRK2 can be specifically cleaved by caspase-3 (and/or caspase-3-like subfamily members) during apoptosis.

Images





Western blot detection of PRK2 in HUVEC,A549,Jurkat,K562 and Hela cell lysates using PRK2 mouse mAb (1:500 diluted).Predicted band size:140KDa.Observed band size:140KDa.




Western blot analysis using PRK2 mouse mAb against PC-12 (1), Cos7 (2), K562 (3), Jurkat (4), Hela (5), A431 (6), C6 (7), NIH/3T3 (8) and HEK293 (9) cell lysate.

Flow cytometric analysis of NIH/3T3 cells using PRK2 mouse mAb (blue) and negative control (red).





Immunohistochemical analysis of paraffin-embedded prostate tissues using PRK2 mouse mAb with DAB staining.



Immunohistochemical analysis of paraffin-embedded lung cancer tissues using PRK2 mouse mAb with DAB staining.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.